Unibest

Pharmaceutical intermediates

Maribavir Intermediates

4 pharmaceutical intermediates for Maribavir. Indication: Cytomegalovirus Infection.

Submit a ProjectAll intermediates

About Maribavir

Originator
GlaxoSmithKline
Indication
Cytomegalovirus Infection
Approved Date
11/23/2021
NCE Patent
11/23/2026
DS/DP
01/04/2032

Available intermediates

4 intermediates currently listed for Maribavir. Request specifications, documentation or a quotation for any item below.

Maribavir intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
BENZIMIDAVIR176161-24-3//
1,2,3,5-TETRA-O-ACETYL-BETA-L-RIBOFURANOSE144490-03-9//
2-BROMO-5,6-DICHLOROBENZIMIDAZOLE142356-40-9//
4,5-Dichloro-1,2-benzenediamine5348-42-5//

Other programs under M

MaxacalcitolMetoclopramide HClMicafungin SodiumMilvexianMirogabalin besilateMolnupiravirMomelotinib Dihydrochloride MonohydrateMoxifloxacin hydrochloride

Building toward Maribavir?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

Submit a Project Talk to the team

How can we help you?

Receive insights into the latest events and regulatory updates

Sent directly to your email

Get industry insights and Unibest news here

Contact Us →